NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • A Guide to What We Do
    • Activities during COVID-19
    • Strategic Partnership Board
    • Steering Committee
    • Promoting Equality, Diversity and Inclusion in Research
    • Current Vacancies
    • Contact Us
    • Stay in Touch
  • Research
        • OUR 20 RESEARCH THEMES

        • Antimicrobial Resistance and Modernising Microbiology
        • Cardiovascular
        • Clinical Informatics and Big Data
        • Diabetes and Metabolism
        • Gastroenterology and Mucosal Immunity
        • Genomic Medicine
        • Haematology and Stem Cells
        • Imaging
        • Molecular Diagnostics
        • Multi-Modal Cancer Therapies
        • Multi-Morbidity and Long-Term Conditions
        • Musculoskeletal
        • Neurological Conditions
        • Obesity, Diet and Lifestyle
        • Partnerships for Health, Wealth and Innovation
        • Respiratory
        • Stroke and Vascular Dementia
        • Surgical Innovation and Evaluation
        • Technology and Digital Health
        • Vaccines for Emerging and Endemic Diseases
        • Oxford Biomedical Research Centre activities during COVID-19
  • Patient & Public Involvement
    • About Patient and Public Involvement
      • Our Work with Patients and the Public
      • Learn More About Our Research
      • Patient Involvement Blog
      • External Links
    • For Patients, Carers and the Public
      • Current Listings for Involvement
      • REGISTER INTEREST
      • Patient and Public Involvement Workshops
    • PPI Resources for Researchers
      • PPI Strategy
      • A Researcher’s Guide to PPI
      • PPI Resources for Researchers
      • PPI Briefing Notes
      • PPI Case Studies
      • PPI Advisory Group
      • PPI Events for Researchers
      • Post a PPI Listing
      • Public Engagement for Researchers
      • Public Engagement Case Studies
  • Training Hub
    • Training Hub
    • Fellowships
    • Funding Opportunities
    • Clinical Researchers and Scientists
    • Nurses, Midwives and Allied Health Professionals
    • Next Generation Leaders Programme
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • What Can We Do For Your Organisation?
    • Who Do We Work With?
    • IP and Licensing
    • Contacts for Industry
  • Videos
  • News
  • Events

News

You are here: Home > Multi-Modal Cancer Therapies > Classification system uncovers new information about ovarian cancers

Classification system uncovers new information about ovarian cancers

18 January 2021 · Listed under Multi-Modal Cancer Therapies

An Oxford-based ovarian cancer specialist has published a paper outlining a new classification which categorises different subtypes of cells and determines which ones can lead to more severe cancer outcomes.

Prof-Ahmed Ahmed-(Image: Ovarian Cancer Action)

This approach, dubbed the ‘Oxford Classification of Carcinoma of the Ovary’ or ‘Oxford Classic’ for short, was developed by Professor Ahmed Ahmed, who is supported by the NIHR Oxford Biomedical Research Centre.

In 2020, using single cell RNA sequencing, Prof Ahmed’s team made a breakthrough by identifying new types of fallopian tube cells that are the cells of origin for the majority of ovarian cancers.

They showed that that the types of these newly-discovered non-cancer cells are ‘mirrored’ into different ovarian cancer subtypes. These subtypes correlated well with survival.

Discovering the new subtypes of cells has allowed the Oxford researchers to classify and categorise tumours based on their origin in the body, and determine which ones can lead to more severe cancer outcomes.

This Oxford Classic approach will provide much more accurate predictions for disease outcome in patients, as well as helping researchers to develop targeted therapies for each type of cancer

Prof Ahmed, of the Nuffield Department of Women’s and Reproductive Health and Director of the Ovarian Cancer Cell Laboratory at the Weatherall Institute of Molecular Medicine, has how published a paper in collaboration with Imperial College demonstrating the applications of the Oxford Classic approach, as well as shedding light on some previously unknown information about ovarian cancers.

Prof Ahmed said: “Our group is very excited that we were able to confirm the predictive role of the Oxford Classic. This work highlights that it is now important to identify new personalised therapies for the Oxford Classic-defined EMT-high ovarian cancer subtype.

“The finding that there is a strong connection with abundant M2 Macrophages already offers a good hint as to where we could find good treatment options for patients with this type.”

Read more via the Cancer Research UK Oxford Centre.

Read the fully study.

← Using AI to improve the quality of endoscopy videos

News

  • Oxford academics named NIHR Senior Investigators 3 March 2021
  • New centre aims to help companies conduct more efficient trials 26 February 2021
  • Oxford study reveals public attitudes to vaccine roll-out programmes 23 February 2021
See full news archive

News Categories

Month Archives

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced bimonthly and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Oxford BRC on Social Media

  • Facebook
  • Twitter
  • YouTube

Feedback

We’d love to hear your feedback. Please contact us at obrcenquiries@ouh.nhs.uk

  • Sitemap
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2021 NIHR Oxford Biomedical Research Centre

Cookies

This site uses cookies See our data control and privacy page